| Title |
Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
|
|---|---|
| Published in |
CNS Drugs, June 2014
|
| DOI | 10.1007/s40263-014-0168-0 |
| Pubmed ID | |
| Authors |
Carmen Tur, Xavier Montalban |
| Abstract |
At present, three risk factors for the development of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients have been identified: the presence of antibodies against JC virus (JCV); the duration of natalizumab treatment, especially if longer than 2 years; and the use of immunosuppressants prior to receiving natalizumab. The most commonly used strategy to assess the individual PML risk includes serum anti-JCV antibody testing. Based on the knowledge on all known risk factors, an algorithm for PML risk stratification has been proposed, where patients with the highest PML risk are those with positive anti-JCV antibodies, treatment duration longer than 2 years, with or without prior history of immunosuppression. These patients would have an approximate incidence of PML of 11.1 (with prior immunosuppression) or 4.6 (without prior immunosuppression) cases per 1,000 patients treated with natalizumab (and treatment duration longer than 2 years). In this review, new data on PML risk factors and possible new strategies for PML risk stratification are discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 3% |
| Brazil | 1 | 3% |
| United Kingdom | 1 | 3% |
| Spain | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 34 | 87% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 26% |
| Student > Ph. D. Student | 10 | 26% |
| Other | 5 | 13% |
| Student > Bachelor | 4 | 10% |
| Librarian | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 2 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 49% |
| Neuroscience | 6 | 15% |
| Agricultural and Biological Sciences | 4 | 10% |
| Immunology and Microbiology | 2 | 5% |
| Nursing and Health Professions | 1 | 3% |
| Other | 4 | 10% |
| Unknown | 3 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 May 2022.
All research outputs
#7,444,605
of 22,757,541 outputs
Outputs from CNS Drugs
#672
of 1,305 outputs
Outputs of similar age
#73,575
of 228,247 outputs
Outputs of similar age from CNS Drugs
#11
of 22 outputs
Altmetric has tracked 22,757,541 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,305 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,247 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.